Neurotoxicity

The development of chimeric antigen receptor T-cell therapy has revolutionized treatment for patients with advanced blood cancers.

Hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases appeared to better preserve cognitive function and improve patient-reported outcomes, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.

ORLANDO — Nearly three-quarters of a cohort of patients with relapsed or refractory large B-cell lymphoma responded to treatment with lisocabtagene maraleucel, according to results of the phase 1 multicenter TRANSCEND-NHL-001 trial presented at TCT | Transplantation & Cellular Therapy Meetings.

Researchers have found evidence countering the hypothesis that a long duration of untreated psychosis is associated with “insidious, severe psychotic disorder,” as well as against the toxicity of untreated psychosis, according to study findings published in American Journal of Psychiatry.

ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response rates in patients with relapsed/refractory large B-cell lymphoma who received CAR T-cell treatment, according to study results presented in a video at ASH Annual Meeting and Exposition.

ORLANDO — Younger patients who receive chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia may develop brain abnormalities that can take a month or more to resolve, according to interim results of an ongoing prospective, longitudinal study presented at ASH Annual Meeting and Exposition.

Imagine a young adult male in his late 20s picks up his cell phone and calls his mother. Overtly emotional and on the verge of releasing a full-out flow of tears, the young man says to the voice at the other end of the line, “Mom, there’s hope.”